Background Malignancies are molecularly complex and become more resistant with each
line of therapy. We hypothesized that offering matched, individualized combination therapies …

Purpose: EGFR exon 20 insertions (ex20ins) are an uncommon genotype in non–small cell
lung cancer (NSCLC) for which targeted therapies are under development. We sought to …

Introduction Targeted therapies have transformed treatment of driver-mutated metastatic
NSCLC. We compared cardiovascular adverse events between and within targeted therapy …

PURPOSE Although NRG1 fusions are oncogenic drivers across multiple tumor types
including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 …

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing
efforts for its early detection by screening populations at risk, the majority of lung cancer …

Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a
model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher …

Cancer of unknown primary (CUP) is a rare malignancy that presents with metastatic
disease and no identifiable site of origin. Most patients have unfavorable features and …

Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …

Targeted drugs and precision medicine have transformed the landscape of cancer therapy
and significantly improved patient outcomes in many cases. However, as therapies are …

CRISPR-based cancer dependency maps are accelerating advances in cancer precision
medicine, but adequate functional maps are limited to the most common oncogenes. To …